Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.

导出 OA

翻译打印收藏纠错

第一作者： Preetesh,Jain

第一单位： Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

作者： Preetesh,Jain ^[1] ; Shuangtao,Zhao ^[2] ; Hun Ju,Lee ^[1] ; Holly A,Hill ^[1] ; Chi Young,Ok ^[3] ; Rashmi,Kanagal-Shamanna ^[3] ; Fredrick B,Hagemeister ^[1] ; Nathan,Fowler ^[1] ; Luis,Fayad ^[1] ; Yixin,Yao ^[1] ; Yang,Liu ^[1] ; Omar B,Moghrabi ^[1] ; Lucy,Navsaria ^[1] ; Lei,Feng ^[4] ; Graciela M,Nogueras Gonzalez ^[4] ; Guofan,Xu ^[5] ; Selvi,Thirumurthi ^[6] ; David,Santos ^[7] ; Cezar,Iliescu ^[8] ; Guilin,Tang ^[3] ; L Jeffrey,Medeiros ^[3] ; Francisco,Vega ^[3] ; Michelle,Avellaneda ^[1] ; Maria,Badillo ^[1] ; Christopher R,Flowers ^[1] ; Linghua,Wang ^[2] ; Michael L,Wang ^[1]

作者单位： Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[1] Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[2] Department of Hemato-pathology, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[3] Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[4] Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[5] Department of Gastroenterology, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[6] Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[7] Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[8]